KR920700293A - 결정형 r-h-GM-CSF 및 이의 제조방법 - Google Patents
결정형 r-h-GM-CSF 및 이의 제조방법Info
- Publication number
- KR920700293A KR920700293A KR1019910700126A KR910700126A KR920700293A KR 920700293 A KR920700293 A KR 920700293A KR 1019910700126 A KR1019910700126 A KR 1019910700126A KR 910700126 A KR910700126 A KR 910700126A KR 920700293 A KR920700293 A KR 920700293A
- Authority
- KR
- South Korea
- Prior art keywords
- csf
- leu
- glu
- thr
- pro
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 11
- 238000000034 method Methods 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 108010034529 leucyl-lysine Proteins 0.000 claims 2
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 claims 1
- ICRHGPYYXMWHIE-LPEHRKFASA-N Arg-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ICRHGPYYXMWHIE-LPEHRKFASA-N 0.000 claims 1
- GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 claims 1
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 claims 1
- WKKKNGNJDGATNS-QEJZJMRPSA-N Cys-Trp-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKKKNGNJDGATNS-QEJZJMRPSA-N 0.000 claims 1
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 claims 1
- VOLVNCMGXWDDQY-LPEHRKFASA-N Gln-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O VOLVNCMGXWDDQY-LPEHRKFASA-N 0.000 claims 1
- JNEITCMDYWKPIW-GUBZILKMSA-N Gln-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JNEITCMDYWKPIW-GUBZILKMSA-N 0.000 claims 1
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 claims 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 claims 1
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 claims 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 claims 1
- RNVUQLOKVIPNEM-BZSNNMDCSA-N His-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O RNVUQLOKVIPNEM-BZSNNMDCSA-N 0.000 claims 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 claims 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 claims 1
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 claims 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 claims 1
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 claims 1
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 claims 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 claims 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 claims 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 claims 1
- AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 claims 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 claims 1
- JXVXYRZQIUPYSA-NHCYSSNCSA-N Pro-Val-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JXVXYRZQIUPYSA-NHCYSSNCSA-N 0.000 claims 1
- KCFKKAQKRZBWJB-ZLUOBGJFSA-N Ser-Cys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O KCFKKAQKRZBWJB-ZLUOBGJFSA-N 0.000 claims 1
- GRSLLFZTTLBOQX-CIUDSAMLSA-N Ser-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N GRSLLFZTTLBOQX-CIUDSAMLSA-N 0.000 claims 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 claims 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 claims 1
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 claims 1
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 claims 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 claims 1
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 claims 1
- VISUNEBASWEMCU-SZMVWBNQSA-N Trp-Glu-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N VISUNEBASWEMCU-SZMVWBNQSA-N 0.000 claims 1
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 claims 1
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 claims 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 claims 1
- 108010005233 alanylglutamic acid Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 108010060199 cysteinylproline Proteins 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010078144 glutaminyl-glycine Proteins 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 108010009298 lysylglutamic acid Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010085203 methionylmethionine Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 108010048818 seryl-histidine Proteins 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/145—Colony stimulating factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Glass Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음
Description
내용없음
Claims (10)
- 결정형 사람 재조합 GM－CSF.
- 제1항에 있어서, 하기의 아미노산 서열을 갖는 결정형 GM－CSF.(H) Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp Glu His Val Asn Ala lle Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp Thr Ala Ala Glu Mrt Asn Glu Thr Val Glu Val lle Ser Glu Met Phe Asp Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser Cys Ala Thr Gln lle lle Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys Asp Phe Leu Leu Val lle Pro Phe Asp Cys Trp Glu Pro Val Gln Glu (OH).
- GM－CSF의 용액이 더욱 농축되도록 하고 GM－CSF결정이 형성되도록 하는 용액에 대하여 GM－CSF의 용액을 평형시킴을 특징으로 하여(이에 의한 GM－CSF의 평형된 용액은 분자량이 약 8,000인 폴리에틸렌 글리콜 및 GM－CSF 40 내지 250mg/ml를 함유한다), 결정형 GM－CSF를 제조하는 방법.
- 제3항에 있어서, 평형을 초여과 또는 투석의 수단으로 수행하거나 방울을 사용하여 수행하는 방법.
- 제3항 또는 4항에 있어서, 평형을 현수방울 또는 샌드위치된 방울로 수행하는 방법.
- 제3항 내지 5항중 어느 한항에 있어서, r－h－GM－CSF의 용액을 폴리에틸렌 글리콜 용액에 대하여 평형시키는 방법.
- 제6항에 있어서, 폴리에틸렌 글리콜 용액중의 폴리에틸렌 글리콜이 약 8,000의 분자량을 갖는 방법.
- 제6항 또는 제7항에 있어서, GM－CSF의 용액이 적합한 완충액을 함유하고 폴리에틸렌 글리콜 용액중의폴리에틸렌 글리콜 농도가 GM－CSF의 용액중에서 보다 더 높은 방법.
- 제8항에 있어서, 완충액이 6.5 내지 8.5pH를 갖는 방법.
- 결정형 사람 재조합 GM－CSF 및 약제학적으로 허용되는 담체를 함유하는 약제 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US362187 | 1989-06-06 | ||
| US07/362,187 US5109119A (en) | 1989-06-06 | 1989-06-06 | Crystalline r-h-gm-csf and method |
| US362,187 | 1989-06-06 | ||
| PCT/US1990/003027 WO1990015151A1 (en) | 1989-06-06 | 1990-06-04 | Crystalline r-h-gm-csf and method for the preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920700293A true KR920700293A (ko) | 1992-02-19 |
| KR960004454B1 KR960004454B1 (ko) | 1996-04-06 |
Family
ID=23425041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910700126A KR960004454B1 (ko) | 1989-06-06 | 1990-06-04 | 결정형 r-h-GM-CSF의 제조방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5109119A (ko) |
| EP (3) | EP0561429A1 (ko) |
| JP (1) | JP2572160B2 (ko) |
| KR (1) | KR960004454B1 (ko) |
| AT (1) | ATE110113T1 (ko) |
| AU (1) | AU644083B2 (ko) |
| CA (1) | CA2058441C (ko) |
| DE (1) | DE69011586T2 (ko) |
| DK (1) | DK0402070T3 (ko) |
| FI (1) | FI915709A0 (ko) |
| HK (1) | HK184996A (ko) |
| HU (1) | HU209871B (ko) |
| NO (1) | NO914771L (ko) |
| WO (1) | WO1990015151A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002063A1 (en) * | 1989-08-11 | 1991-02-21 | Amrad Corporation Limited | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof |
| EP0668914B1 (en) * | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US6004549A (en) * | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| PE20020394A1 (es) * | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| IL159524A0 (en) | 2001-07-11 | 2004-06-01 | Maxygen Holdings Ltd | G-csf conjugates |
| US7765302B2 (en) * | 2003-06-30 | 2010-07-27 | Nortel Networks Limited | Distributed call server supporting communication sessions in a communication system and method |
| WO2006019950A2 (en) * | 2004-07-16 | 2006-02-23 | Nektar Therapeutics Al, Corporation | Conjugates of a gm-csf moiety and a polymer |
| RU2007149238A (ru) | 2005-06-01 | 2009-07-20 | Максиджен Холдингз Лтд. (Ky) | Пегилированные полипептиды гксф и способы их получения |
| WO2007102946A2 (en) * | 2006-01-23 | 2007-09-13 | Amgen Inc. | Crystalline polypeptides |
| CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU588819B2 (en) * | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| CN1020473C (zh) * | 1984-11-20 | 1993-05-05 | 先灵生物技术公司 | 编码表现有人粒性巨噬细胞和嗜伊红细胞生长因子活性之多肽的cDNA克隆 |
| JP2595216B2 (ja) * | 1986-12-12 | 1997-04-02 | 日清製粉株式会社 | α―アミラーゼインヒビターの結晶の製造方法 |
| US4912200A (en) * | 1987-05-11 | 1990-03-27 | Schering Corporation | Extraction of granulocyte macrophage colony stimulating factor from bacteria |
| EP0377023B1 (en) * | 1988-05-31 | 1995-02-15 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
-
1989
- 1989-06-06 US US07/362,187 patent/US5109119A/en not_active Expired - Fee Related
-
1990
- 1990-06-04 AT AT90306042T patent/ATE110113T1/de not_active IP Right Cessation
- 1990-06-04 JP JP2509088A patent/JP2572160B2/ja not_active Expired - Lifetime
- 1990-06-04 CA CA002058441A patent/CA2058441C/en not_active Expired - Fee Related
- 1990-06-04 DK DK90306042.4T patent/DK0402070T3/da active
- 1990-06-04 KR KR1019910700126A patent/KR960004454B1/ko not_active IP Right Cessation
- 1990-06-04 EP EP19930108721 patent/EP0561429A1/en not_active Withdrawn
- 1990-06-04 DE DE69011586T patent/DE69011586T2/de not_active Expired - Fee Related
- 1990-06-04 AU AU58348/90A patent/AU644083B2/en not_active Ceased
- 1990-06-04 EP EP90909434A patent/EP0476022A1/en active Pending
- 1990-06-04 WO PCT/US1990/003027 patent/WO1990015151A1/en not_active Application Discontinuation
- 1990-06-04 HU HU904835A patent/HU209871B/hu not_active IP Right Cessation
- 1990-06-04 EP EP90306042A patent/EP0402070B1/en not_active Expired - Lifetime
-
1991
- 1991-12-04 FI FI915709A patent/FI915709A0/fi not_active Application Discontinuation
- 1991-12-04 NO NO91914771A patent/NO914771L/no unknown
-
1995
- 1995-06-07 US US08/482,168 patent/US5616555A/en not_active Expired - Lifetime
-
1996
- 1996-10-03 HK HK184996A patent/HK184996A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2058441A1 (en) | 1990-12-07 |
| ATE110113T1 (de) | 1994-09-15 |
| DE69011586D1 (de) | 1994-09-22 |
| NO914771D0 (no) | 1991-12-04 |
| HU904835D0 (en) | 1992-02-28 |
| HU209871B (en) | 1994-11-28 |
| AU5834890A (en) | 1991-01-07 |
| EP0476022A1 (en) | 1992-03-25 |
| EP0402070A1 (en) | 1990-12-12 |
| JPH04502014A (ja) | 1992-04-09 |
| JP2572160B2 (ja) | 1997-01-16 |
| DK0402070T3 (da) | 1994-09-12 |
| AU644083B2 (en) | 1993-12-02 |
| US5109119A (en) | 1992-04-28 |
| CA2058441C (en) | 1997-12-16 |
| NO914771L (no) | 1991-12-04 |
| HK184996A (en) | 1996-10-11 |
| FI915709A0 (fi) | 1991-12-04 |
| HUT58822A (en) | 1992-03-30 |
| DE69011586T2 (de) | 1995-03-02 |
| EP0402070B1 (en) | 1994-08-17 |
| EP0561429A1 (en) | 1993-09-22 |
| KR960004454B1 (ko) | 1996-04-06 |
| WO1990015151A1 (en) | 1990-12-13 |
| US5616555A (en) | 1997-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920700293A (ko) | 결정형 r-h-GM-CSF 및 이의 제조방법 | |
| Howard et al. | Studies on a phytohemagglutinin from the lentil: II. Multiple forms of Lens Culinaris hemagglutinin | |
| Scawen et al. | The action of proteolytic enzymes on the glycoprotein from pig gastric mucus | |
| Petermann et al. | The Ultracentrifugal Analysis of Diphtheria Proteins. | |
| RU1837880C (ru) | Способ разделени белков крови | |
| US5387746A (en) | Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof | |
| AU9052891A (en) | Proteins with changed epitopes and methods for the production thereof | |
| KR920701255A (ko) | 에리쓰로포이에틴 동형체(eryihropoietin isoform) | |
| TW427905B (en) | Aqueous pharmaceutical composition of nerve growth factor | |
| EP0134385A3 (en) | A protein having cell growth stimulating action, composition thereof and method for producing the same | |
| AU2387088A (en) | Cationized antibodies for delivery through the blood-brain barrier | |
| US4075193A (en) | Process for producing intravenous immune globulin | |
| Jagschies et al. | Bovine fatty acid binding proteins: Isolation and characterisation of two cardiac fatty acid binding proteins that are distinct from corresponding hepatic proteins | |
| WO1987006943A1 (en) | Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof | |
| EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
| CA2126680A1 (en) | Novel megakaryocyte potentiator | |
| KR940010024B1 (ko) | α-인터페론의 제조 및 정제 방법 | |
| Lamblin et al. | Isolation and immunological properties of neutral bronchial mucins from a patient with chronic bronchitis | |
| KR900001848A (ko) | 단백질 | |
| JP3486196B2 (ja) | ストレプトリジンｏの精製方法、この方法により得られる完全ストレプトリジンｏおよびその使用 | |
| RU95113498A (ru) | Линейные или циклические олигопептиды, обладающие сродством к опиоидным рецепторам, фармацевтическая композиция, способ лечения | |
| JPH0654659A (ja) | 甘味誘導物質ミラクリンの製造方法 | |
| LAPRESLE et al. | Structural differences between rabbit cathepsin E and cathepsin D | |
| Takeuchi et al. | Purification of human lung angiotensin-converting enzyme by high-performance liquid chromatography: Properties and N-terminal amino acid sequence | |
| EP0327769A3 (en) | Novel neuronotrophic factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |